CD274 and neoplasm: The decision was strategic, as SD-101 in combination with pembrolizumab exhibited promising anti-tumor activity in the phase 1b/2 SYNERGY-001/KEYNOTE-184 study (NCT02521870) of PD-(L)1 inhibitor-naive patients with metastatic melanoma or recurrent/metastatic SCCHN.